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A B S T R A C T
Objective: Pathological changes within the hypothalamus have been proposed to mediate circadian rhythm and
habitual sleep disturbances in individuals with Huntington’s disease (HD). However, investigations examining
the relationships between hypothalamic volume and circadian rhythm and habitual sleep in individuals with HD
are sparse. This study aimed to comprehensively evaluate the relationships between hypothalamic pathology
and circadian rhythm and habitual sleep disturbances in individuals with premanifest HD.
Methods: Thirty-two individuals with premanifest HD and twenty-nine healthy age- and gender-matched con-
trols participated in this dual-site, cross-sectional study. Magnetic resonance imaging scans were performed to
evaluate hypothalamic volume. Circadian rhythm and habitual sleep were assessed via measurement of morning
and evening cortisol and melatonin levels, wrist-worn actigraphy, the Consensus Sleep Diary and sleep ques-
tionnaires. Information on mood, physical activity levels and body composition were also collected.
Results: Compared to healthy controls, individuals with premanifest HD displayed significantly reduced grey
matter volume in the hypothalamus, decreased habitual sleep efficiency and increased awakenings; however, no
alterations in morning cortisol or evening melatonin release were noted in individuals with premanifest HD.
While differences in the associations between hypothalamic volume and cortisol and melatonin output existed in
individuals with premanifest HD compared to healthy controls, no consistent associations were observed be-
tween hypothalamic volume and circadian rhythm or habitual sleep outcomes.
Conclusion: While significant differences in associations between hypothalamic volume and cortisol and mela-
tonin existed between individuals with premanifest HD and healthy controls, no differences in circadian markers
were observed between the groups. This suggests that circadian regulation is maintained despite hypothalamic
pathology, perhaps via neural compensation. Longitudinal studies are required to further understand the re-
lationships between the hypothalamus and circadian rhythm and habitual sleep disturbances in HD as the
disease course lengthens.
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1. Introduction
Circadian rhythm and habitual sleep disturbances are common
features of Huntington’s disease (HD) that occur early in the disease
course and exacerbate impairments in cognitive function, metabolism,
hormone regulation, mood and quality of life (Aziz et al., 2010;
Briançon-Marjollet et al., 2015; Lazar et al., 2015; Morton et al., 2005).
A number of studies have reported dysregulation of markers of
circadian rhythm and habitual sleep-wake outcomes in individuals with
HD. In particular, increased morning cortisol output has been reported
in individuals with premanifest HD (Hubers et al., 2015; van Duijn
et al., 2010). Reduced mean and acrophase concentrations and a tem-
poral spread of melatonin release, indicating a potential phase shift in
melatonin, have been reported in individuals with premanifest HD
(Kalliolia et al., 2014). Furthermore, studies have reported disruption of
the sleep-wake cycle and delayed sleep phase in individuals with HD
(Aziz et al., 2010; Morton et al., 2005). Despite these findings, the
neurobiological origin of circadian rhythm and habitual sleep-wake
disturbances in individuals with HD has been poorly investigated and
warrants further exploration.
Pathological changes within the hypothalamus have been proposed
to disrupt circadian rhythm and sleep in individuals with HD (Aziz
et al., 2010; Morton et al., 2005). Hypothalamic nuclei, particularly the
suprachiasmatic nucleus, are known to be integrally involved in the
regulation of circadian markers such cortisol and melatonin, as well as
sleep (Saper et al., 2005; Steiger, 2002). Studies have reported grey
matter volume loss and microglial activation within the hypothalamus
and circadian rhythm and sleep disturbances that arise concomitantly
in individuals with premanifest HD (Lazar et al., 2015; Morton et al.,
2005; Politis et al., 2008; Soneson et al., 2010). Despite these findings,
only one study has examined the potential link between neural pa-
thology and circadian rhythm and sleep disturbances in individuals
with HD (Baker et al., 2016). Baker et al. (2016) reported an association
between subjective sleep disturbances and neural pathology in HD.
However, the authors did not use formalised sleep questionnaires to
examine sleep and did not evaluate markers of circadian rhythm re-
lative to neural pathology. There is, therefore, a need for subsequent
research to investigate more closely the potential relationships between
hypothalamic pathology and circadian rhythm and sleep disturbances
in HD.
The purpose of this study was to evaluate whether hypothalamic
pathology is associated with the dysregulation of biological and clinical
markers of circadian rhythm, particularly cortisol, melatonin and sleep-
wake timing, and habitual sleep in individuals with premanifest HD. We
hypothesized that hypothalamic pathology would be associated with
dysregulation of circadian rhythm and habitual sleep, as evidenced by
significant alterations in cortisol and melatonin release and habitual
sleep-wake cycles in individuals with premanifest HD.
2. Materials and methods
2.1. Participants
Thirty-five premanifest HD individuals and 31 age- and gender-
matched healthy controls were recruited from existing databases, HD
clinics and media advertisements in Perth and Melbourne. Inclusion
criteria for premanifest HD individuals were a cytosine-adenine-gua-
nine (CAG) repeat length ≥ 40 and a diagnostic confidence score< 2
on the Unified Huntington’s Disease Rating Scale Total Motor Score
(UHDRS-TMS) (Reilmann et al., 2014). Exclusion criteria for all parti-
cipants were, presence of known musculoskeletal, metabolic, endo-
crine, cardiovascular or sleep disorders, recent or long-standing sub-
stance abuse, shift work other neurological conditions and, for healthy
controls, a family history of HD. Five participants withdrew from the
study or contributed incomplete data and were excluded from analyses,
leading to a total of 32 premanifest HD and 29 healthy individuals.
All aspects of the study were conducted in accordance with the
Declaration of Helsinki. Ethical approval was granted by the Edith
Cowan University and Monash University Human Research Ethics
Committees. All participants provided written informed consent.
2.2. Study procedures
Testing procedures included 3T MRI scans for hypothalamic ima-
ging, saliva sampling to quantify morning cortisol and evening mela-
tonin, wrist-worn actigraphy for monitoring sleep, a sleep diary for
monitoring habitual sleep patterns and questionnaires for monitoring
sleep quality, psychological stress, physical activity, anxiety and de-
pression.
2.3. Acquisition and pre-processing of MRI data
T1-weighted structural images of the brain were obtained from each
participant in Perth or Melbourne using a GE Healthcare Discovery and
a Siemens Skyra 3T MRI scanner, respectively. In Perth, images were
acquired with a 24-channel head coil using an IR-SPGR sequence (TA =
9m 59 s, TR = 3 s, TE = Min, TI = 400 ms, flip angle = 11°, field of
view = 256mm, image matrix = 256 × 256, 1mm3 isotropic voxels).
In Melbourne, acquisition took place with a 32-channel head coil and
an MP-RAGE sequence (TA= 9m 14 s, TR = 2.3 s, TE = 2.96 ms, TI =
900 ms, flip angle = 9°, field of view = 256mm, image matrix = 256
× 256). Images were acquired consistently across both sites according
to the Alzheimer’s Disease Neuroimaging Initiative protocols for multi-
site imaging (Jack et al., 2008). Pre-processing of images was con-
ducted according to the SPM12 pipeline (Supplementary data).
2.4. Measurement of biological markers of circadian rhythm
Salivary cortisol and melatonin have previously been shown to be
useful measures of circadian rhythm (Dickmeis, 2009; Voultsios et al.,
1997). Participants were given written and verbal instructions to collect
saliva samples by passive drool into polypropylene collection tubes (SSI
Bio) at the same time on two consecutive days for determination of
morning cortisol and evening melatonin concentrations. Participants
collected saliva samples at four time points in the morning (15, 30, 45
and 60min following awakening) for morning cortisol analysis and four
time points in the evening at one hour intervals from two hours before
their usual bedtime (T1) until one hour after their usual bedtime (T4)
for melatonin analysis. Saliva samples were collected according to cri-
teria from previous studies (van Duijn et al., 2010; Voultsios et al.,
1997) to avoid contamination of samples (see Supplementary files).
Based on these criteria, a questionnaire was devised to monitor parti-
cipant compliance. Saliva samples were stored at−80 °C until analysis
using commercially available salivary cortisol and melatonin ELISA kits
(Salimetrics, USA) according to the manufacturer’s instructions.
2.5. Measures of habitual sleep-wake parameters
2.5.1. Actigraphy
At the commencement of the study, a convenience sample of in-
dividuals with premanifest HD and healthy controls were given the
opportunity to undertake habitual sleep monitoring using actigraphy.
Of the original cohort, 19 premanifest HD and 24 healthy individuals
underwent home-based actigraphy sleep measurement for seven con-
secutive nights to assess habitual sleep-wake patterns. Actigraphy was
recorded at 30 Hz using wrist-worn GT3X+ ActiGraph monitors
(ActiGraph, USA) on the non-dominant wrist. The start and end time of
sleep periods were recorded using the Consensus Sleep Diary (Carney
et al., 2012).
Wrist-based actigraphy has been used previously to assess circadian
rhythm via analysis of habitual sleep-wake patterns in individuals with
HD and in other populations (Ancoli-Israel et al., 2003; Morton et al.,
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2005). Therefore, here we similarly used ActiGraph monitors, which
were initialised, downloaded and analysed using the ActiLife software
(version 6.8). Data were scored with a low frequency extension filter in
60 s epochs as awake or sleep according to the Cole-Kripke algorithm
(Cole et al., 1992). Total sleep time, sleep onset latency, wake after
sleep onset, number of awakenings and sleep efficiency outcomes were
calculated for each night and then averaged across the seven nights to
obtain single values for use in subsequent analyses.
2.5.2. Consensus sleep diary
Habitual sleep-wake timing was evaluated using the Consensus
Sleep Diary (Carney et al., 2012). Participants were required to docu-
ment time in bed, time of awakening, time to sleep onset, number of
awakenings and sleep quality for seven nights in combination with
actigraphy assessment.
2.5.3. Subjective sleep quality and daytime somnolence
Sleep quality was assessed in all participants using the Pittsburgh
Sleep Quality Index (PSQI) (Buysse et al., 1989). Daytime somnolence
was measured using the Epworth Sleepiness Scale (ESS) (Johns, 1991).
2.6. Stress, anxiety and depression symptomatology
The Perceived Stress Scale (Cohen et al., 1983) was used to measure
psychological stress in the previous month. The Perceived Stress Scale
has been demonstrated to be a valid measure of perceived psychological
stress in individuals with HD (Downing et al., 2011). Symptoms of
anxiety and depression were measured using the Hospital Anxiety and
Depression Scale (HADS). This scale has been previously demonstrated
to be valid and reliable in HD (De Souza et al., 2010).
2.7. Physical activity
Physical activity levels were recorded prior to and during saliva
sampling days using the Minnesota Leisure Time Physical Activity
Questionnaire. Metabolic equivalents (METs) were calculated using
recorded physical activity levels, the Compendium of Physical
Activities database and estimated resting metabolic rate (RMR)
(Ainsworth et al., 2011). RMR was calculated using the Harris-Benedict
formula (see Supplementary file) (Harris and Benedict, 1918).
2.8. Statistical analysis
2.8.1. Hypothalamic volume
A hypothalamus mask from the WFU Pick Atlas (http://fmri.w-
fubmc.edu/software/pickatlas), dilated by 3mm, was used to restrict
analysis to this area (Breen et al., 2016). Grey matter images from in-
dividuals with premanifest HD and healthy controls were compared
voxel-wise using a two-sample t-test to evaluate group differences in the
hypothalamus. Gender, site and age were included as covariates of no
interest. Next, we investigated group differences in the association be-
tween hypothalamic volume and cortisol and/or melatonin output in
individuals with premanifest HD compared to healthy controls, using a
categorical by continuous covariate interaction model. The model in-
cluded group regressors, one for each group, and regressors modelling
change in cortisol or melatonin output, one for each group. The fol-
lowing contrasts were used to model the group by cortisol/melatonin
output interaction effect: [0 0 1−1] and [0 0−1 1]. Gender, site, age,
PSS, ESS, and PSQI were included as covariates of no interest. In pre-
manifest HD, we adjusted also for CAP score.
We also evaluated the relationship between hypothalamic volume
and disease status (i.e. CAP score). Given the exploratory nature of this
study and our a priori interest in the hypothalamus, the threshold for
statistical significance for all analyses was set at α = 0.05.
2.8.2. Salivary cortisol and melatonin
Missing data points from saliva sampling (removed due to suspected
blood contamination) were imputed by calculating the average of the
participant’s previous and subsequent values in the curve (n= 2 of 504,
0.40%), unless the missing value was the first time point in each curve
(n= 3 of 504, 0.60%), in which case the group average was imputed to
avoid removing the participant from analyses and maintain sample size
(van Duijn et al., 2010). Area under the curve with respect to ground
(AUCG) was calculated using the trapezoid rule for morning cortisol and
evening melatonin output on the two consecutive days (Dijk et al.,
2012; van Duijn et al., 2010).
Normality assumptions for all variables were tested using a Shapiro-
Wilk test. Between-group differences were examined using a t-test for
continuous variables and a two sample proportion test for categorical
variables. Spearman correlation coefficient was calculated to assess
relationships between cortisol AUCG, melatonin AUCG and Perceived
Stress Scale, PSQI and Consensus Sleep Diary scores. Statistical sig-
nificance was set at p≤ 0.05. Statistical analyses were performed using
STATA version 9.1.
3. Results
3.1. Participant demographics and clinical characteristics
There were no significant differences for age or gender between
premanifest HD patients and healthy controls (p = 0.472 and 0.283,
respectively; Table 1).
Table 1
Demographic and clinical characteristics of premanifest Huntington's disease
and healthy control participants.
Premanifest HD
(n=32)
Healthy
Controls
(n=29)
p-value
Demographic Characteristics
Age, mean± SD 44.5± 11.4 44.3± 10.8 0.472
Male, n (%) 11 (34.4) 8 (27.6) 0.283
Clinical Characteristics
CAGn, mean±SD 42.8± 2.8 N/A N/A
Estimated age of onset,
median (IQR)
47.4 (44.9–55.7) N/A N/A
Diagnostic Confidence
Level, mean±SD
0.38± 0.70 N/A N/A
UHDRS-TMS, mean± SD 4.35± 7.24 N/A N/A
Disease burden score, mean
± SD
305.0± 76.8 N/A N/A
CAPs, mean±SD 0.89± 0.18 N/A N/A
BMI, mean± SD 26.47± 4.5 26.75± 5.9 0.417
Smoker, n (%) 6 (18.8) 0 (0.0) 0.007*
High alcohol consumption,
n (%)**
5 (15.6) 6 (20.7) 0.303
Psychotropic medication, n
(%)
3 (9.4) 5 (17.2) 0.181
Monthly METs, mean± SD 3278.0±6272.5 7481.2±9584.5 0.022*
METs (previous day), mean
± SD
168±359.2 85.1± 211.8 0.141
Group differences were analysed using t-tests for continuous variables and two
sample proportion tests for categorical variables. Disease burden score was
calculated using the formula: age x (CAGn – 35.5). CAPs was calculated using
the formula: (age x (CAGn - 33.66))/432.3326.
HD = Huntington's disease; CAGn = number of cytosine-adenine-guanine re-
peats; UHDRS-TMS = Unified Huntington's Disease Rating Scale-Total Motor
Score; CAPs = scaled CAG age product score; BMI = body mass index; MET=
metabolic equivalents; METs (previous day) refers to the METs calculated for
the day prior to saliva sampling; N/A = not applicable.
* Results are significant at p<0.05
** High alcohol consumption equates to in excess of 14 alcoholic drinks per
week
D.M. Bartlett et al. Neurobiology of Sleep and Circadian Rhythms 6 (2019) 1–8
3
Fig. 1. Results from voxel-based morphometry analyses showing overlap between maps of (A) the hypothalamic volume group difference, (B) association between
hypothalamus loss and CAPs in premanifest HD, (C) group by cortisol output interaction and (D) group by melatonin output interaction. (E) shows the map of group
by cortisol output interaction effect on hypothalamic volume (as per voxel-wise analysis) and a scatterplot illustrating the interaction and (F) shows the map of group
by melatonin output interaction effect on hypothalamic grey matter volume and scatterplot illustrating the interaction. The data points in the scatterplot correspond
to the average intensity across all voxels within the area exhibiting a significant interaction effect for each participant. Slice labels are displayed on top. Cross-slices
are shown. Crosshairs in (A), (B), (C), and (D) are centred at MNI -9 1 -5. L= left; R= right.
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3.2. Hypothalamic volume
A significant decrease in grey matter volume in the anterior-su-
perior region of the left side of the hypothalamus was observed in in-
dividuals with premanifest HD compared to healthy controls (peak
voxel at MNI -9 1 -4; t = 2.38; k = 22; see Fig. 1A). We also found a
significant negative association in premanifest HD between grey matter
volume bilaterally in the anterior-superior and anterior-inferior regions
of the hypothalamus and CAP score (r= -0.42; see Table 3 and Fig. 1B).
3.3. Biological markers of circadian rhythm
No significant differences were observed between individuals with
premanifest HD and healthy control participants in the amplitude of
morning cortisol or evening melatonin output at any of the time points
sampled (p>0.05; Table 2). Furthermore, no differences were ob-
served in total morning cortisol (p= 0.357) or evening melatonin (p=
0.219) output when subject to area under the curve analysis with re-
spect to ground (AUCG; Table 2).
3.4. Habitual sleep outcomes
3.4.1. Actigraphy
Premanifest HD individuals exhibited a decreased sleep efficiency
compared to healthy controls (p = 0.012). A significant increase in the
number of awakenings (p = 0.039) and time spent awake after sleep
onset (p = 0.028) were also observed in premanifest HD participants
compared to healthy controls (Table 2).
3.4.2. Consensus sleep diary
No significant differences were observed in self-report sleep out-
comes using the Consensus Sleep Diary (Table 2).
3.4.3. Subjective sleep outcomes
There were no significant differences between premanifest HD in-
dividuals and healthy controls in global PSQI score (p = 0.134). The
average PSQI score in the premanifest HD group fell above the cut-off of
5, suggesting a disruption in sleep quality. Although healthy controls
scored significantly higher than premanifest HD individuals on the ESS,
scores for both groups remained within the normative range (< 10)
(Johns, 1991).
3.5. Stress, anxiety and depression questionnaires
No significant differences were observed in stress (p = 0.062), an-
xiety (p = 0.164) or depression (p = 0.427) symptomatology between
premanifest HD and healthy individuals (Table 2). Furthermore, values
on the Perceived Stress Scale and HADS were considered below
threshold, indicating no clinically meaningful stress, anxiety or de-
pressive symptomatology in the premanifest HD and healthy control
groups.
3.6. Physical activity
The premanifest HD group reported significantly less monthly
physical activity (METs) than healthy controls (p = 0.022; Table 1).
Physical activity on the day prior to saliva sampling did not differ be-
tween the groups, negating any acute effects of physical activity on
hormone levels. Furthermore, there was no association between re-
ported physical activity levels and measures of sleep, cortisol and
melatonin output and hypothalamic volume.
3.7. Associations between hypothalamic volume and circadian markers
A significant negative association was revealed by voxel-wise ana-
lysis between grey matter volume in the left hypothalamus and morning
cortisol output in the premanifest HD group. This association was found
to be moderate (r= -0.39), indicating that lesser grey matter volume in
the left side of the hypothalamus is associated with greater morning
cortisol output. No significant association was observed in the healthy
control group (Fig. 1E and Table 3). This group difference in the as-
sociation between hypothalamic volume and morning cortisol output
Table 2
Cortisol and melatonin values, subjective and objective sleep outcomes and
stress, anxiety and depression questionnaire scores for premanifest Huntington's
disease and healthy control participants.
Premanifest HD Healthy
Controls
p-value
Cortisol nmol/L (mean±SD)
Time of awakening (hh:mm) 6:06± 1:01 6:21± 0:45 0.141
Time of sample relative to
awakening:
+15min 11.08± 4.40 11.28±3.32 0.421
+30min 13.84± 4.59 13.42±4.29 0.357
+45min 13.69± 3.56 13.30±4.41 0.352
+60min 12.26± 3.47 11.62±3.72 0.244
AUCG 38.17± 11.30 39.20±10.61 0.357
Melatonin (pg/mL)
Reported usual bedtime (hh:mm) 22:05± 0:50 22:10±0:31 0.322
Time of sample relative to
bedtime:
-2 h 10.87± 7.68 10.02±6.19 0.319
-1 h 12.16± 7.07 13.71±7.84 0.210
+0 h 17.10± 9.30 19.44±11.10 0.187
+1 h 19.42± 12.02 22.07±11.11 0.188
AUCG 49.20± 25.88 44.41±21.77 0.219
Actigraphy measures:
Total time in bed (min) 464.28± 46.73 458.58± 43.10 0.680
Total sleep time (min) 403.17± 45.20 415.12± 40.25 0.365
Sleep onset latency (min) 7.10± 6.80 4.39± 3.77 0.106
Wake after sleep onset (min) 54.02± 25.97 39.07±16.87 0.028*
Number of awakenings 18.47± 6.72 14.55±5.33 0.039*
Average duration of awakenings
(min)
2.87± 0.64 2.75± 0.87 0.625
Sleep efficiency (%) 86.98± 5.42 90.68±3.75 0.012*
PSQI global score 5.76± 3.02 4.97± 2.44 0.134
Epworth Sleepiness Scale Score 4.69± 3.61 6.76± 3.37 0.025*
Consensus Sleep Diary:
Total time in bed (min) 430.42± 61.33 434.84± 68.48 0.372
Total sleep time (min) 385.82± 53.90 387.92± 74.77 0.453
Sleep onset latency (min) 16.65± 19.90 14.35±13.92 0.303
Wake after sleep onset (min) 19.04± 25.37 16.93±22.89 0.412
Sleep efficiency 90.52± 5.17 89.32±9.96 0.487
Number of awakenings 1.25± 1.47 1.75± 1.03 0.057
Average duration of awakenings
(min)
10.18± 23.46 8.97± 11.11 0.059
Restorative quality of sleep 3.75± 0.81 3.80± 0.92 0.411
Perceived Stress Scale 17.12± 6.72 19.86±6.85 0.062
HADS:
Total score 7.54± 5.30 8.38± 5.69 0.276
Anxiety 5.06± 3.48 6.00± 3.97 0.164
Depression 2.49± 2.52 2.38± 2.14 0.427
Data are reported as mean and standard deviation, unless stated otherwise.
Group differences were analysed using t-tests. AUCG was calculated using the
trapezoid rule for morning cortisol and evening melatonin output using the
curve generated from the average cortisol values and the average melatonin
values, respectively. Sleep efficiency was calculated using the formula: (total
sleep time/total time in bed) X 100. PSQI score greater than 5 indicates poor
sleepers. The Consensus Sleep Diary- restorative quality of sleep item is a Likert
scale ranging from 1 (not restorative) to 5 (very restorative). Higher Perceived
Stress Scale scores indicate greater stress. HADS sub-scores greater than 7 in-
dicate clinically relevant anxiety and depression symptomatology.
HD= Huntington's disease; AUCG= area under the curve with respect to
ground; PSQI= Pittsburgh Sleep Quality Index; HADS= Hospital Anxiety and
Depression Scale.
* Results are significant at p<0.05.
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was statistically significant, as shown by interaction analysis (Fig. 1C,
Fig. 1E and Table 3). The group by cortisol output interaction en-
compassed two separate areas – first, the region spanning the posterior
hypothalamus and the superior tuberal hypothalamus and second, the
anterior-inferior hypothalamic region.
A negative relationship between grey matter volume in the right
side of the hypothalamus and morning cortisol output was seen in
healthy controls, but not in premanifest HD participants, and the group
by cortisol output interaction was significant (Table 3). However, the
association between right hypothalamic grey matter volume and
morning cortisol output in healthy controls was weak (r = -0.06), in-
dicating a non-existent relationship in this case.
Grey matter volume in the left side of the hypothalamus was posi-
tively associated with evening melatonin output in healthy controls (r
= 0.36), but not in premanifest HD individuals (Fig. 1F and Table 3).
This group difference in the correlation between hypothalamic volume
and evening melatonin output was statistically significant (Fig. 1D,
Fig. 1F and Table 3). The group by melatonin output interaction en-
compassed the region extending from the superior tuberal hypotha-
lamus to the anterior-inferior hypothalamus.
3.8. Associations between hypothalamic volume and habitual sleep
outcomes
No reliable pattern of associations was observed between hypotha-
lamic volume and measures of subjective sleep quality, sleep onset la-
tency, number of awakenings, sleep efficiency or perceived stress in the
premanifest HD or healthy cohorts.
4. Discussion
Hypothalamic pathology and disturbances in circadian rhythm and
sleep arise during the premanifest stages of HD. Despite the central role
of the hypothalamus in mediating the circadian rhythm and sleep-wake
timing, only one study has attempted to discern the possible relation-
ship between hypothalamic pathology and sleep disturbances in in-
dividuals with HD (Baker et al., 2016). In the absence of robust data,
the aim of this study was to examine the potential relationship between
hypothalamic pathology and circadian rhythm and habitual sleep out-
comes in individuals with premanifest HD.
Consistent with previous findings (Soneson et al., 2010), sig-
nificantly reduced grey matter volume was observed in the hypotha-
lamus of individuals with premanifest HD compared to healthy con-
trols. Using normative parcellations of the hypothalamus that rely on
visible anatomic landmarks in MR images (Makris et al., 2013), this
reduced grey matter volume can be located to the anterior-superior
region of the hypothalamus, a region comprising the paraventricular
nucleus (PVN), which mediates the release of cortisol and melatonin.
Reduced hypothalamic volume was found to be associated with CAP
score, suggesting a relationship between estimated time to disease onset
and loss of hypothalamic grey matter volume. Interestingly, degenera-
tion within the hypothalamus was leftward biased. The reason for this is
unknown. Studies have reported a leftward-biased pattern of grey
matter atrophy in the striatum in individuals with manifest HD
(Minkova et al., 2018; Mühlau et al., 2007), however, this has not been
reported in the striatum or the hypothalamus in individuals with pre-
manifest HD. Minkova et al. (2018) postulated that the earliest patho-
logical changes in the hypothalamus occur on the left side and become
more apparent as individuals approach clinical onset, however addi-
tional research is needed to support this supposition.
The pathological mechanisms responsible for reduced hypothalamic
volume in individuals with HD are not yet understood. Evidence from
post-mortem investigations and studies in mouse models provides in-
sight into potential mechanisms by which hypothalamic changes could
occur, as well as mechanisms by which these changes could impact on
circadian rhythm and habitual sleep outcomes. For example, neuronal
inclusions of mutant huntingtin in suprachiasmatic nucleus (SCN) tissue
at post-mortem (Aziz et al., 2008), may directly mediate changes in the
functioning of the SCN. Such neuronal inclusions of mutant huntingtin
within the SCN could reduce the number of vasoactive intestinal
polypeptide and arginine vasopressin expressing neurons, which are
crucial in the regulation of SCN activity (Aton et al., 2005; Hofman and
Swaab, 1994), as well as post-transcriptional changes in these neuro-
peptides, which have been reported in HD (van Wamelen et al., 2013).
These changes, together with a loss of orexin-releasing neurons in the
lateral hypothalamus which has been reported in individuals with HD
at post-mortem and in mouse models of HD (Aziz et al., 2008; Petersén
et al., 2005), could result in impaired functioning of the hypothalamic
nuclei and lead to the disruption of the circadian rhythm and sleep-
wake cycle that has been reported in individuals with HD and in HD
mouse models (Kudo et al., 2011; Loh et al., 2013; Morton, 2013;
Morton et al., 2005). These potential mechanisms are complex and
interrelated and require further investigation.
The reduction in hypothalamic grey matter volume in individuals
with premanifest HD was significantly associated with morning cortisol
release. This relationship was not observed in healthy controls.
Conversely, the association between hypothalamic volume and evening
melatonin concentrations observed in healthy controls was absent in
individuals with premanifest HD. Both the group by cortisol output and
the group by melatonin output interaction effect on hypothalamic grey
matter volume occurred across regions encompassing the SCN and the
PVN. Despite significantly reduced habitual sleep efficiency and an
increase in the number of awakenings and time spent awake after sleep
onset in individuals with premanifest HD, which aligns with previous
reports of sleep disturbances in premanifest HD (Lazar et al., 2015),
hypothalamic volume was not significantly associated with habitual
sleep outcomes. The lack of consistent associations between hypotha-
lamic volume and habitual sleep outcomes was unexpected, especially
considering the known role of the hypothalamus in regulating the sleep-
wake cycle via the SCN and its connections with the ventrolateral
preoptic nucleus and the lateral area within the hypothalamus (Bartlett
et al., 2016; Saper et al., 2005).
While inconsistent relationships were observed between hypotha-
lamic volume and habitual sleep outcomes, further studies should assess
the impact of reduced hypothalamic volume on changes in the under-
lying sleep electroencephalogram, which is reported to be altered in HD
mouse models and in individuals with HD (Fisher et al., 2013; Fisher
et al., 2016; Kantor et al., 2013; Lazar et al., 2015; Piano et al., 2017).
Such analyses would allow further characterisation of the impact of
hypothalamic changes on sleep outcomes in HD.
Table 3
Association analyses between hypothalamic volume and CAPs, cortisol and
melatonin.
Side k Peak voxel
t score MNI coordinates
CAPs
Negative association with CAPs in
premanifest HD
B 204 3.16 -3 2 -7
Cortisol
Negative association with cortisol
output in premanifest HD
L 161 2.54 -10 1 -4
Group by cortisol output interaction L 186 2.32 -10 1 -4
Melatonin
Positive association with melatonin
output in healthy controls
L 161 2.67 -10 1 -6
Group by melatonin output interaction L 201 2.41 -6 2 -8
Group differences were analysed using two-sample t-tests.
*Results are significant at p<0.05, uncorrected.
k = No. of voxels; MNI = Montreal Neurological Institute; HD = Huntington's
disease; B = bilateral; L = left.
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Despite observing differences in the relationships between hy-
pothalamic grey matter volume and cortisol and melatonin in the pre-
manifest HD cohort compared to healthy controls, no differences in
morning cortisol or evening melatonin release were observed between
the two groups, which is contradictory to previous reports (Kalliolia
et al., 2014; van Duijn et al., 2010). It is important to note that a large
proportion of our premanifest HD cohort were females (65.6%). This is
of relevance as sex-specific differences in circadian rhythm dysfunction
have been reported in HD mouse models (Kuljis et al., 2016). In par-
ticular, female HD mice exhibit less severe or delayed changes in ac-
tivity levels and behavioural fragmentation compared to male HD mice
(Kuljis et al., 2016). Therefore, the lack of differences in cortisol and
melatonin release between individuals with premanifest HD and
healthy controls may be related to sex-specific effects.
Conceivably, the right side of the hypothalamus, or indeed other
structures involved in the release of cortisol and melatonin, such as the
pituitary or pineal glands, may be able to compensate for the reduced
hypothalamic volume during the premanifest stages of the disease and
thereby maintain normal regulation of cortisol and melatonin release.
This is supported by emerging evidence indicating the presence of
compensatory neural functions in individuals with HD (Gregory et al.,
2017; Scheller et al., 2014). This theory nevertheless requires further
validation in larger longitudinal studies.
This study is not without limitations. Firstly, current imaging
methods are not yet sensitive enough to capture the individual nuclei
within the hypothalamus; however, parcellation approaches that rely
on anatomic landmarks visible on MR images (e.g. Makris et al., 2013)
allow the distinction of the different hypothalamic regions, which af-
fords some insight into which structures may be affected. Secondly, this
study evaluated cortisol and melatonin regulation using saliva sam-
pling, which is known to be more variable than blood sampling.
However, salivary cortisol and melatonin sampling was preferred to
blood sampling as previous studies indicate that blood sampling ele-
vates cortisol levels (Weckesser et al., 2014). Thirdly, this study in-
cluded a large proportion of females with HD, which may have influ-
enced our ability to find significant differences in cortisol/melatonin
release between individuals with premanifest HD and healthy controls.
Discrepancies in cortisol and melatonin findings between this study and
others may also reflect differences in measurement protocols (i.e., fre-
quency of sampling time points), patient characteristics or seasonal
differences (Kalliolia et al., 2014; Stothard et al., 2017; van Duijn et al.,
2010). A lack of concordance also existed between the habitual sleep
measures, potentially due to differences in reporting methods (i.e.
subjective versus objective). No evidence of elevated stress, anxiety or
depression was noted, indicating that mood disorders did not impact on
markers of circadian rhythm or habitual sleep. Future studies should
assess the relationship between hypothalamic pathology and sleep ar-
chitecture in individuals with premanifest HD using polysomnography.
In summary, our findings show that individuals with premanifest
HD exhibit leftward biased hypothalamic pathology that is differen-
tially associated with markers of circadian rhythm, but not consistently
associated with habitual sleep-wake deficits, when compared to healthy
controls. However, the lack of differences in concentrations of markers
of circadian rhythm between the two groups suggests the possibility of
neural compensation, facilitated by the right hemisphere of the hy-
pothalamus or by other brain structures involved in the circadian and
sleep cycles, as a mechanism involved in maintaining the regulation of
the circadian rhythm and habitual sleep-wake function in individuals
with premanifest HD. Larger, longitudinal studies are required to fur-
ther investigate the role of hypothalamic pathology in circadian rhythm
and habitual sleep-wake disturbances in HD as the disease course
lengthens.
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